Anti-Cancer Nuclear Receptor-Targeted Compounds for Selective PARP Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
PARP inhibitors used in cancer treatment cause significant side effects like neutropenia due to rapid dose-dependent development, limiting their long-term efficacy, and existing compounds lack targeted delivery and cell-type selectivity.
Innovation Solution
Development of compounds comprising a nuclear payload and a nuclear receptor-targeting epitope that bind to specific nuclear receptors, allowing targeted delivery and accumulation in tumor cells, enhancing tumor cell death while sparing normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PARP inhibitors are used to treat cancer, then tumor growth inhibition is achieved, but neutropenia develops rapidly and dose-dependently
Solution Approach 1:
The compound is divided into distinct functional modules: a nuclear payload (PARP inhibitor) and a nuclear receptor-targeting epitope. This segmentation allows the payload to be selectively delivered to specific cell types expressing the target receptor, thereby achieving tumor growth inhibition while sparing normal cells from toxic effects like neutropenia
Solution Approach 2:
The compound exhibits local quality by being selectively active only in cells that express the specific nuclear receptor (e.g., androgen receptor, estrogen receptor). This selective localization of therapeutic effect to receptor-positive tumor cells while avoiding receptor-negative normal cells resolves the contradiction between efficacy and toxicity
2Productivity
If PARP inhibitors are administered at high doses to achieve maximal efficacy, then tumor growth inhibition improves, but neutropenia develops more rapidly and severely
Solution Approach 1:
By segmenting the compound into a payload and a targeting epitope, the invention enables selective delivery of the PARP inhibitor to tumor cells expressing the specific nuclear receptor. This allows achieving maximal efficacy at lower overall doses, avoiding the dose-dependent neutropenia that plagues conventional PARP inhibitor therapy
Solution Approach 2:
The nuclear receptor-targeting epitope acts as an intermediary that mediates selective delivery of the PARP inhibitor to the nucleus of target cells. This intermediary mechanism enables high local concentration of the payload at the site of action while maintaining low systemic exposure, thereby achieving maximal efficacy without proportionally increasing toxicity
3Adaptability or versatility
If conventional chemotherapeutic agents are used, then broad anti-tumor activity is achieved, but side effects increase and therapeutic index decreases
Solution Approach 1:
The compound exhibits local quality by being selectively active only in cells that express the specific nuclear receptor. This selective localization of therapeutic effect to receptor-positive tumor cells while avoiding receptor-negative normal cells resolves the contradiction between efficacy and toxicity
Solution Approach 2:
The nuclear receptor-targeting epitope serves as an intermediary that directs the PARP inhibitor payload specifically to target cells. This intermediary mechanism provides cell-type selectivity, enabling broad anti-tumor activity against receptor-positive tumors while sparing normal cells, thereby improving the therapeutic index
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds achieve superior efficacy in cancer treatment by preferentially targeting tumor cells, reducing side effects and improving therapeutic index through selective nuclear receptor binding and payload delivery.
Implementation Method 1
compounds comprising at least one nuclear payload and at least one nuclear receptor-targeting epitope. Compounds described herein are designed to bind nuclear receptors within the cell and allow the compound, with its nuclear payload, to accumulate in the nucleus
Implementation Method 2
by accumulating preferentially in the of nuclear receptor positive cells, such as steroid receptor positive cells, spare cells that do not express the specific nuclear steroid receptor, and therefore reduce side effects
Data Source
AI summary
The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.